 | Up a level |
Rob, Lukas 
ORCID: 0000-0003-3770-651X, Cibula, David ORCID: 0000-0001-6387-9356, Knapp, Pawel, Mallmann, Peter, Klat, Jaroslav, Minar, Lubos, Bartos, Pavel, Chovanec, Josef, Valha, Petr, Pluta, Marek, Novotny, Zdenek, Spacek, Jiri, Melichar, Bohuslav, Kieszko, Dariusz, Fucikova, Jitka, Hrnciarova, Tereza, Korolkiewicz, Roman Pawel, Hraska, Marek, Bartunkova, Jirina and Spisek, Radek
(2022).
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
J. Immunother. Cancer, 10 (1).
LONDON:
BMJ PUBLISHING GROUP.
ISSN 2051-1426
Rob, Lukas, Bartunkova, Jirina, Cibula, David ORCID: 0000-0001-6387-9356, Knapp, Pawel ORCID: 0000-0003-3008-616X, Namestkova, Zurana, Splsek, Radek, Waclav, Jan and Mallmann, Peter
(2014).
Autologous dendritic cell vaccination (DCVAC/OvCa) added to standard of care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer (OC).
J. Clin. Oncol., 32 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755